Butyrate, a short-chain fatty acid produced by the fermentation of dietary fiber by gut microbiota, plays a critical role in maintaining intestinal health and has significant implications for Clostridioides difficile (C. difficile) infection.
Butyrate, a short-chain fatty acid produced by the fermentation of dietary fiber by gut microbiota, plays a critical role in maintaining intestinal health and has significant implications for Clostridioides difficile (C. difficile) infection. C. difficile is a major public health concern, causing hundreds of thousands of infections and thousands of deaths annually. It is often associated with antibiotic use, which disrupts the gut microbiota, leading to dysbiosis and reduced levels of butyrate-producing bacteria. This creates a favorable environment for C. difficile colonization and overgrowth.
Butyrate contributes to intestinal homeostasis by nourishing colonocytes (intestinal cells), strengthening the gut barrier, and modulating inflammation. Research has shown that a butyrate-rich gut environment can suppress C. difficile by inhibiting its colonization and reducing its virulence. Specifically, butyrate affects bacterial metabolism, toxin production, and sporulation, key factors in the pathogenesis of C. difficile infection.
Conversely, low butyrate levels, often caused by antibiotic-induced dysbiosis, weaken the gut's defenses and increase susceptibility to infection. Understanding the interplay between butyrate, gut microbiota, and C. difficile could pave the way for novel therapies. Strategies to restore butyrate levels, such as microbiome restoration, dietary interventions, or butyrate supplementation, may offer safer and more sustainable alternatives to traditional antibiotic treatments.
Introduction: Anal squamous cell carcinoma is an increasingly common but largely preventable cancer. Most cases arise from persistent high-risk human papillomavirus (HPV) infection, progressing through high-grade squamous intraepithelial lesions (HSIL). This comprehensive review summarizes the...
Introduction: Acute infectious gastroenteritis can trigger persistent gastrointestinal symptoms long after the infection has resolved, leading to post-infection disorders of gut-brain interaction (PI-DGBI). This global Rome Foundation study evaluated the prevalence, risk factors, and clinical...
Introduction: Gut microbiota alterations have been implicated in the pathogenesis of irritable bowel syndrome (IBS), making fecal microbiota transplantation (FMT) a promising therapeutic strategy. However, clinical trials have reported conflicting results. This updated meta-analysis evaluated...
Introduction: Laparoscopic adhesiolysis offers several short-term advantages over open surgery for adhesive small bowel obstruction (ASBO). However, its long-term impact on recurrence, quality of life, and incisional hernia remains uncertain. The LASSO trial provides the...
Introduction: Growing evidence suggests that Parkinson's disease (PD) may originate in the gut, with pathological α-synuclein spreading to the brain through the vagus nerve. This study investigated whether sitagliptin, a widely used DPP-4 inhibitor for...
Introduction: Necrotizing enterocolitis (NEC) is one of the most serious gastrointestinal emergencies in neonates. Early identification of infants requiring surgical intervention is critical but remains challenging. This study compared bedside abdominal ultrasonography (US) with abdominal...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.